Wiseking Medical Robot (Hangzhou) Co., Ltd., a surgical robotics company affiliated with Kangji Medical, has announced the completion of a B+ financing round worth several hundred million RMB. The round was solely invested by Guotai Junan Innovation Investment, with Kangji Medical participating as a strategic follow-on investor. G&G Capital acted as the exclusive financial advisor.

According to the company, the proceeds will be used primarily to accelerate commercialization of its approved products and to advance R&D and clinical registration of next-generation surgical robotic systems.

From Long-Term Technical Accumulation to Scalable Products

Wiseking Medical’s technology base originates from its core team’s long-standing research in minimally invasive surgical robotics. The company has focused on key surgical challenges including precision, stability, and real-time visual feedback, and has developed a relatively complete system-level technology stack covering motion control, image-transmission latency reduction, and mechanical drive compensation.

Its flagship product, a four-arm laparoscopic surgical robot, received regulatory approval from China’s National Medical Products Administration (NMPA) in 2025. This milestone marks the system’s transition from R&D into a regulated clinical and commercial phase, enabling broader deployment in real-world surgical settings.

• High-precision master–slave control with force feedback: Features a master–slave architecture with variable-impedance force feedback, tremor filtering, and master-side force compensation, achieving sub-0.5 mm repeatability accuracy to enhance surgical precision, comfort, and control.

• Compact dual-screen 4K visualization with flexible channel design: Equipped with a compact dual-screen 4K display and endoscope–instrument channel compatibility. The system uses an ultra-slim endoscope—among the smallest in its class—enabling intraoperative interchangeability between endoscopic and instrument channels for flexible, multi-angle visualization.

• Comprehensive in-house instrument portfolio, including ultrasonic scalpel: Supports a full range of self-developed biomimetic instruments, covering powered and non-powered, rigid and flexible, therapeutic and auxiliary tools. Its proprietary ultrasonic scalpel features extended shaft length for expanded reach, is reusable up to five times, and is optimized for 3–5 mm vessel sealing, meeting common laparoscopic surgical needs.

From a market perspective, the system is positioned for routine laparoscopic minimally invasive procedures, emphasizing operational stability, visual clarity, and fine motor control—attributes closely aligned with current clinical expectations for domestically developed robotic systems that are practical, substitutable, and sustainable in daily use.

Following regulatory approval, Wiseking’s robotic system has entered pilot and early clinical use in multiple Class III (top-tier) hospitals across China, involving surgeons with varied backgrounds. Rather than focusing on a single center of excellence, the company appears to be moving toward multi-center validation, a critical step in assessing system robustness and adaptability across different hospital environments.

At the industry level, Wiseking benefits from clear strategic alignment with Kangji Medical, which has an extensive hospital network built through its established portfolio of minimally invasive surgical instruments and consumables. This overlap with the target user base for laparoscopic robots creates a “system + instruments + consumables” synergy, potentially lowering hospitals’ overall adoption barriers and increasing integration into real clinical workflows.

Such vertical collaboration may become an important competitive factor as Chinese surgical robotics companies enter the commercialization phase and increasingly compete with established international players.

January 12, 2026, MedChina